Gender-modulated impact of apolipoprotein A5 gene (APOA5) −1131T>C and c.56C>G polymorphisms on lipids, dyslipidemia and metabolic syndrome in Turkish adults
-
Evrim Komurcu-Bayrak
, Altan Onat , Mehves Poda , Steve E. Humphries , Jutta Palmen , Filiz Guclu , Gunay Can and Nihan Erginel-Unaltuna
Abstract
Background: Apolipoprotein A5 (APOA5) gene polymorphisms are usually associated with plasma triglyceride levels. We evaluated the relationship of the APOA5 −1131T>C and c.56C>G polymorphisms [single nucleotide polymorphism (SNP)] with serum lipids, dyslipidemia [low high-density lipoprotein (HDL)/high triglyceride] and the risk for metabolic syndrome (MS) in the Turkish Adult Risk Factor study.
Methods: We genotyped SNPs using the Taqman allelic discrimination assays in 1564 Turkish adults (51.4% female, mean age 54.1±11.6 years). MS and dyslipidemia were defined using the criteria of the National Cholesterol Education Program.
Results: For both SNPs, rare allele carriers had significantly higher fasting triglyceride levels in both genders, except the c.56G allele in men. The −1131C allele was associated with lower HDL cholesterol (HDL-C) levels in women. In relation to dyslipidemia, the c.56C>G and haplotype 1 had significant gender-genotype interactions (p<0.05). Otherwise, both SNPs were significantly associated with dyslipidemia after adjustment for risk factors in women. After similar adjustment, non-carriers of the haplotype 1 (odds ratio=4.1, p=0.003) increased the MS risk in women. However, no significant associations emerged between SNPs and HDL-C, dyslipidemia or MS in a similar analysis in men.
Conclusions: Excess risk for low HDL-C, dyslipidemia and MS is associated with the rare alleles of the APOA5 SNPs and non-carriers of common haplotype in women.
Clin Chem Lab Med 2008;46:778–84.
©2008 by Walter de Gruyter Berlin New York
Articles in the same Issue
- Reviews
- The STANISLAS Cohort: a 10-year follow-up of supposed healthy families. Gene-environment interactions, reference values and evaluation of biomarkers in prevention of cardiovascular diseases
- Cardiovascular biomarkers: increasing impact of laboratory medicine in cardiology practice
- Haemolysis: an overview of the leading cause of unsuitable specimens in clinical laboratories
- Cardiovascular Diseases
- APOA5 Ala315>Val, identified in patients with severe hypertriglyceridemia, is a common mutation with no major effects on plasma lipid levels
- Gender-modulated impact of apolipoprotein A5 gene (APOA5) −1131T>C and c.56C>G polymorphisms on lipids, dyslipidemia and metabolic syndrome in Turkish adults
- Oxidative stress markers, C-reactive protein and heat shock protein 70 levels in subjects with metabolic syndrome
- Development of sensitive and specific age- and gender-specific low-density lipoprotein cholesterol cutoffs for diagnosis of first-degree relatives with familial hypercholesterolaemia in cascade testing
- Distribution of plasma cardiac troponin I values in healthy subjects: pathophysiological considerations
- High-density lipoprotein cholesterol and paraoxonase 1 (PON1) genetics and serum PON1 activity in prepubertal children in Spain
- Genetics and Molecular Diagnostics
- Polymorphisms of CYP17A1, CYP19, and androgen in Brazilian women with uterine leiomyomas
- A novel MEN1 frameshift germline mutation in two Italian monozygotic twins
- The silent hemoglobin α chain variant Hb Riccarton [α51(CE9)Gly→Ser] may affect HbA1c determination on the HLC-723 G7 analyzer
- General Clinical Chemistry and Laboratory Medicine
- Urinary fructose-1,6-bisphosphatase activity as a marker of the damage to the renal proximal tubules in children with idiopathic nephrotic syndrome
- Antioxidant defense capacity in scleroderma patients
- Correction of ventricular cerebrospinal fluid (CSF) samples for blood content does not increase sensitivity and specificity for the detection of CSF infection
- Validation and Outcome Studies
- Preanalytical quality control program – an overview of results (2001–2005 summary)
- A laboratory-based risk score for medical intensive care patients
- Analytical performance evaluation of the Cobas 6000 analyzer – special emphasis on trueness verification
- Letters to the Editor
- Quality planning and analytical quality requirements derived from biology
- Importance of sample size in hospital point-of-care glucose measurements
- Reliability of M protein quantification: comparison of two peak integration methods on Capillarys 2
- What's in a name? Standardization of HbA1c
- Serum paraoxonase 1 activities and homocysteinemia in hemodialysis patients
Articles in the same Issue
- Reviews
- The STANISLAS Cohort: a 10-year follow-up of supposed healthy families. Gene-environment interactions, reference values and evaluation of biomarkers in prevention of cardiovascular diseases
- Cardiovascular biomarkers: increasing impact of laboratory medicine in cardiology practice
- Haemolysis: an overview of the leading cause of unsuitable specimens in clinical laboratories
- Cardiovascular Diseases
- APOA5 Ala315>Val, identified in patients with severe hypertriglyceridemia, is a common mutation with no major effects on plasma lipid levels
- Gender-modulated impact of apolipoprotein A5 gene (APOA5) −1131T>C and c.56C>G polymorphisms on lipids, dyslipidemia and metabolic syndrome in Turkish adults
- Oxidative stress markers, C-reactive protein and heat shock protein 70 levels in subjects with metabolic syndrome
- Development of sensitive and specific age- and gender-specific low-density lipoprotein cholesterol cutoffs for diagnosis of first-degree relatives with familial hypercholesterolaemia in cascade testing
- Distribution of plasma cardiac troponin I values in healthy subjects: pathophysiological considerations
- High-density lipoprotein cholesterol and paraoxonase 1 (PON1) genetics and serum PON1 activity in prepubertal children in Spain
- Genetics and Molecular Diagnostics
- Polymorphisms of CYP17A1, CYP19, and androgen in Brazilian women with uterine leiomyomas
- A novel MEN1 frameshift germline mutation in two Italian monozygotic twins
- The silent hemoglobin α chain variant Hb Riccarton [α51(CE9)Gly→Ser] may affect HbA1c determination on the HLC-723 G7 analyzer
- General Clinical Chemistry and Laboratory Medicine
- Urinary fructose-1,6-bisphosphatase activity as a marker of the damage to the renal proximal tubules in children with idiopathic nephrotic syndrome
- Antioxidant defense capacity in scleroderma patients
- Correction of ventricular cerebrospinal fluid (CSF) samples for blood content does not increase sensitivity and specificity for the detection of CSF infection
- Validation and Outcome Studies
- Preanalytical quality control program – an overview of results (2001–2005 summary)
- A laboratory-based risk score for medical intensive care patients
- Analytical performance evaluation of the Cobas 6000 analyzer – special emphasis on trueness verification
- Letters to the Editor
- Quality planning and analytical quality requirements derived from biology
- Importance of sample size in hospital point-of-care glucose measurements
- Reliability of M protein quantification: comparison of two peak integration methods on Capillarys 2
- What's in a name? Standardization of HbA1c
- Serum paraoxonase 1 activities and homocysteinemia in hemodialysis patients